News

Leader in technology joins AmerisourceBergen board

BY Michael Johnsen

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday elected Mark Durcan, 54, to its board of directors, effective immediately. Durcan fills the vacancy created by Edward Hagenlocker’s retirement at the annual meeting of stockholders earlier this year, the company stated.
 
“Mark’s understanding of international markets and his experience managing global manufacturing, procurement and supply chain activities combined with his expertise in technology make him an excellent addition to our board,” said Richard Gozon, chairman of the board of AmerisourceBergen.
 
Durcan is currently CEO and a director of Micron Technology. During Durcan’s tenure as CEO, Micron has become one of the largest chip makers in the world. Under his leadership, Micron has driven its next-generation technologies to market and expanded its global presence and capabilities, developing and maintaining long-standing partnerships with industry leaders, such as Intel, and completing strategic acquisitions all over the world.
 
“Mark is recognized for his strategic vision and focus on technology innovation to drive growth in a highly competitive industry, as well as his success and personal commitment to fostering international partnerships and joint ventures to expand the footprint of a U.S.-based business in key markets all over the world," added Steven Collis, AmerisourceBergen president and CEO. "Mark’s insights will be invaluable as we pursue our long-range plans to increase our international presence and invest in technology to enhance supply chain efficiency and security.”
 
 
Durcan currently serves on the board of directors of Freescale Semiconductor, the Semiconductor Industry Association Board and the Tech CEO Council. He is the Chairman of the Micron Technology Foundation, which was formed to advance science, technology, engineering and math (STEM) education and support civic and charitable institutions in the communities in which Micron employees live and work. 
 
Durcan previously served on the board of MWI Veterinary Supply. He earned both his bachelor’s and master’s degrees in chemical engineering from Rice University. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Nature’s Truth to offer 12-mg melatonin supplements

BY David Salazar

RONKONKOMA, N.Y. — Nature’s Truth, the wholesale brand of Piping Rock Health Products, is looking to shake the VMS aisle with its products — among them its 12-mg melatonin. The product comes in natural berry flavor in bottles of 60 fast-dissolving tabs, and is among the highest-strength melatonin supplements available.

The 12-mg melatonin is also the strongest of Nature’s Truth’s melatonin offerings, alongside the company’s 3- and 5-mg fast-dissolve tabs. Melatonin is part of Nature’s Truth’s larger line of sleep aids, which includes 1200-mg valerian root and L-tryptophan, both of which are available in bottles of 90 quick-release capsules.  

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

CVS Health: Narrow pharmacy networks boost adherence

BY Michael Johnsen

WOONSOCKET, R.I. — Narrow pharmacy networks improve medication adherence, according to a new CVS Health Research Institute study published Tuesday in JAMA Internal Medicine. The study is the first to evaluate the impact of narrow pharmacy networks on medication adherence, the company stated. 
 
In addition, the researchers observed an even greater impact on adherence when there were 90-day prescription programs also in place. 
 
"There are few opportunities in health care when we can improve both quality of care and health outcomes while helping to manage health care costs," stated William Shrank, SVP and chief scientific officer, CVS Health and a study author. "This first-of-its-kind study suggests that narrow networks may be one such opportunity by providing clear evidence that these networks – already an established cost management strategy – also help optimize members' adherence."
 
The researchers reviewed de-identified pharmacy claims data for more than 200,000 patients on chronic therapies to treat high cholesterol, high blood pressure, diabetes and depression over a 12-month period. These patients received prescription drug coverage through CVS' pharmacy benefit management business CVS/caremark. The study found that those patients in commercial drug plans with narrow pharmacy networks had improved medication adherence as indicated by their medication possession ratio, which measures patients' available medication on hand over time and is commonly used as an indication of adherence. 
 
The researchers also found that if 90-day prescription programs, where patients receive a three-month supply of their chronic medication prescription during one pharmacy visit, were used in conjunction with a narrow network there was an even greater improvement in members' adherence. 
 
"Despite common concerns that narrow pharmacy networks reduce access, we believe they can actually help encourage plan members to establish a pharmacy home where patients with chronic diseases can receive coordinated care and effective medication adherence support," Shrank said. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?